Aman U. Buzdar

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Jack Cuzick, Ivana Šestak, Michael Baum et al. · The Lancet Oncology · 2010 · 1.7K citations

Medicine, Oncology, Pharmacology +15

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

W. Fraser Symmans, Florentia Peintinger, Christos Hatzis et al. · Journal of Clinical Oncology · 2007 · 1.7K citations · Full text

Medicine, Oncology, Breast Oncology +16

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Henry M. Kuerer, Lisa A. Newman, Terry L. Smith et al. · Journal of Clinical Oncology · 1999 · 1.3K citations

Medicine, Oncology, Surgery +17

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Jean‐Marc Nabholtz, Aman U. Buzdar, Michaël Pollak et al. · Journal of Clinical Oncology · 2000 · 996 citations

Pharmacy, Oncology, Pharmacotherapy +15